Literature DB >> 19284394

Effects of aggressive approach to the multiple risk factors for diabetic nephro-pathy on proteinuria reduction in diabetes type 2 patients.

Belma Ascić-Buturović1, Mirsad Kacila, Mehmed Kulić.   

Abstract

Dietary interventions with protein and salt restriction, good glucose control, smoking cessation, aggressive blood pressure control, good control of cholesterol and triglycerides, use of ACE inhibitors and ARBs can delay the progression of diabetic nephropathy. The aim of this study was to present the effects of aggressive treatment of the multiple risk factors for diabetic nephropathy on proteinuria in patients with type 2 diabetes. In this study we included 15 patients with diabetes type 2 and insufficient regulation of glycaemia. The patients were followed for three months period. Glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), blood pressure, cholesterol and triglycerides and proteinuria were followed prior and after the study. Prior the study patients were treated with premix insulin divided in two daily doses + metformin after the lunch and they had insufficient regulation of glycaemia. During the study patients were treated with one daily dose of basal insulin, three doses of metformin (2550 mg), one daily dose of atorvastatin (20 mg) and one daily dose of ramipril (5 to 10 mg). Doses of insulin were titrated separately for each patients (0,7-1,0 IU/kg). Patients were advised to start with lifestyle modification, increased physical activity and dietary interventions with protein and salt restriction, energy restricted diet and smoking cessation. A total of 20 patients (male 12 and female 8) with diabetes type 2 were studied. The mean age of the subjects was 53+/-5,25 years. The mean diabetes duration was 4,05+/-1,96 years. The mean body mass index decreased from 28,1+/-1,67 kg/m2 to 25,9 +/-1,22 kg/m2 after the study. Mean HbA1c decreased from 8,82 +/- 0,53 % to 7,15 +/- 0,23 % (p<0,05). Mean fasting glycemia decreased from 8,79+/-0,58 mmol/dm3 to 7,03+/-0,18 mmol/dm3 (p < 0,05). Mean postmeal glycemia decreased from 9,93 +/- 0,77 mmol/dm3 to 7,62 +/- 0,42 mmol/dm3 (p<0,05). The mean cholesterol level decreased from 7,99 +/-0,64 mmol/dm3 to 5,93 +/- 0,65 mmol/dm3 (p<0,05). The mean triglicerides level decreased from 4,05 +/- 0,97 mmol/dm3 to 1,96 +/- 0,24 mmol/dm3 (p<0,05). The significant decrease of proteinuria was recorded, prior the study the mean albuminuria was 1,05 +/- 0,31 g/dm3 and after the study was 0,07 +/- 0,145 g/dm3 (p<0,05). Mean blood pressure prior the study was 153+/-8,69/91,5 +/- 3,78 mm Hg (p<0,05), after the study was 125 +/- 6,32/ 79,25+/-3,26 mmHg. Effective control of glycaemia, blood pressure, cholesterol and triglycerides, use of ACE inhibitors, dietary interventions with protein and salt restriction, smoking cessation, can delay the progression of nephropathy in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284394      PMCID: PMC5645547          DOI: 10.17305/bjbms.2009.2855

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  10 in total

1.  Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.

Authors:  J E Heeg; P E de Jong; G K van der Hem; D de Zeeuw
Journal:  Kidney Int       Date:  1989-08       Impact factor: 10.612

2.  Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria.

Authors:  E R Mathiesen; B Rønn; T Jensen; B Storm; T Deckert
Journal:  Diabetes       Date:  1990-02       Impact factor: 9.461

3.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

4.  Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial.

Authors:  F L Brancati; P K Whelton; B L Randall; J D Neaton; J Stamler; M J Klag
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

5.  Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes.

Authors:  T J Allen; M J Waldron; D Casley; G Jerums; M E Cooper
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

6.  Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota.

Authors:  D J Ballard; L L Humphrey; L J Melton; P P Frohnert; P C Chu; W M O'Fallon; P J Palumbo
Journal:  Diabetes       Date:  1988-04       Impact factor: 9.461

7.  Similar risks of nephropathy in patients with type I or type II diabetes mellitus.

Authors:  C Hasslacher; E Ritz; P Wahl; C Michael
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

8.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

9.  Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation.

Authors:  P H Bennett; S Haffner; B L Kasiske; W F Keane; C E Mogensen; H H Parving; M W Steffes; G E Striker
Journal:  Am J Kidney Dis       Date:  1995-01       Impact factor: 8.860

Review 10.  Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.

Authors:  C E Mogensen
Journal:  J Intern Med       Date:  2003-07       Impact factor: 8.989

  10 in total
  1 in total

1.  Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Debasish Kar; Clare Gillies; Mintu Nath; Kamlesh Khunti; Melanie J Davies; Samuel Seidu
Journal:  Acta Diabetol       Date:  2019-02-24       Impact factor: 4.280

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.